ClinicalTrials.gg
RecruitingNCT07864701PANGU-1Updated Oct 15, 2026

Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers

A Phase 1/2 interventional study of JMBI-001 Tablets in Advance Solid Tumors and Lymphoma, Non-Hodgkin, sponsored by Chengdu Anticancer Bioscience, Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Chengdu Anticancer Bioscience, Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 15, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
42nd of 183
150 · median 58
Started
2026
with 12 others
Phase 1/2
42 of 196
27 open now
Primary completion
2029-06
later than 99 of 109 live
Registered
194th of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 42nd largest by planned enrollment of the 183 interventional ones that give a count, is one of 13 that started in 2026, is one of 42 in phase 1/2, reaches primary completion later than 99 of the 109 other live ones, and was the 194th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.

Read the detailed description

The purpose of this clinical trial is to investigate JMBI-001 for the treatment of MYC-positive advanced tumors and to evaluate its safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and antitumor efficacy.

The main questions this study aims to answer are:

  1. To evaluate the safety, tolerability, PK, and preliminary antitumor activity of JMBI-001, and to determine the recommended dose for expansion (RDE) and the recommended Phase II dose (RP2D).
  2. To evaluate the antitumor efficacy, safety, tolerability, and PK of JMBI-001 at the RP2D in selected tumor types.

Participants will:

  1. Take JMBI-001 orally once daily on an empty stomach for 4 consecutive days, followed by 3 days without treatment. Three such 7-day dosing periods will constitute one 21-day treatment cycle.
  2. Visit the study site as scheduled to undergo protocol-specified procedures, including medical interviews, physical examinations, blood tests, electrocardiograms, and imaging examinations.
  3. Continue treatment until a protocol-defined event requiring discontinuation of study treatment or withdrawal from the study occurs.
03

Conditions studied

  • Advance Solid Tumors
  • Lymphoma, Non-Hodgkin

Keywords

  • MYC-Positive Tumor
  • MKLP2
  • KIF20A
  • JMBI-001
  • MYC
  • Anticancer Bioscience
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to fully understand the study requirements, voluntarily agree to participate in the study, and provide written .
  • Male or female participants aged 18 to 75 years, inclusive.
  • or cytologically confirmed malignant tumor. Participants with solid tumors must have unresectable locally advanced or disease for which standard treatment has failed, is not tolerated, or is unavailable. Participants with non-Hodgkin lymphoma must have received at least two . Tumor-specific requirements for each study phase are as follows:

    1. Phase Ia dose-escalation stage: Solid tumors, including but not limited to gastric cancer, colorectal cancer, non-small cell lung cancer, hepatocellular carcinoma, and triple-negative breast cancer. Non-Hodgkin lymphoma, including but not limited to diffuse large B-cell lymphoma and Burkitt lymphoma.
    2. Phase Ib dose-expansion stage: tumor indications within prespecified tumor types of particular interest, potentially sensitive tumor types or subtypes identified during Phase Ia, or both. Prespecified tumor types of particular interest include, but are not limited to, gastric cancer, colorectal cancer, non-small cell lung cancer, hepatocellular carcinoma, and non-Hodgkin lymphoma.
    3. Phase II indication-expansion stage: selected tumor indications that meet the prespecified transition criteria during Phase Ib.
  • Except for participants enrolled in the accelerated titration stage of Phase Ia, tumor tissue obtained or submitted during screening must be tested by immunohistochemistry and meet the following criteria for MYC positivity:

    1. Solid tumors: MYC-positive tumor cell nuclei in at least 10% of tumor cells.
    2. Non-Hodgkin lymphoma: MYC-positive tumor cell nuclei in at least 40% of tumor cells.
  • At least one lesion suitable for efficacy assessment, as follows:

    1. For participants with solid tumors, at least one according to version 1.1 (RECIST v1.1). The longest diameter must be at least 10 mm on spiral computed tomography, or the short-axis diameter of an enlarged lymph node must be at least 15 mm. A lesion selected as a target lesion must not have received radiotherapy within 4 weeks before the first dose of JMBI-001; palliative local radiotherapy to a non-target lesion is permitted.
    2. For participants with non-Hodgkin lymphoma, according to the Lugano 2014 criteria, the longest diameter must be greater than 1.5 cm for a nodal lesion or greater than 1.0 cm for an extranodal lesion.

Exclusion criteria

Exclusion Criteria:

  • Difficulty swallowing or inability to swallow tablets.
  • Known to any component of JMBI-001 tablets.
  • Carcinomatous meningitis, brainstem , or spinal cord compression confirmed by imaging or clinical diagnosis.
  • History of a severe neurologic disorder or severe psychiatric or psychological disorder that may interfere with the participant's ability to understand or comply with the study protocol.
  • Systemic therapy within 2 weeks before the first dose of JMBI-001 at a prednisone-equivalent dose greater than 10 mg/day.
  • Gastrointestinal disease or abnormality that may affect the absorption of JMBI-001, including but not limited to celiac disease, short bowel syndrome, Crohn disease, ulcerative colitis, gastrointestinal perforation, or severe vomiting or diarrhea.

Other Inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    JMBI-001 Monotherapy

    Participants will receive JMBI-001 orally once daily on an empty stomach for 4 consecutive days, followed by 3 days without treatment. Each 21-day treatment cycle consists of three consecutive 7-day dosing periods.

    Drug: JMBI-001 Tablets

Interventions

  • DrugJMBI-001 Tablets

    JMBI-001 will be administered orally once daily on an empty stomach for 4 consecutive days, followed by 3 days without treatment, in repeated 21-day treatment cycles. Dose levels will be determined according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Phase Ia: dose-limiting toxicities (DLTs)

    Time frame: Cycle 1, Days 1-21 after the first dose (21-day DLT assessment period)

  2. Phase Ia: maximum tolerated dose (MTD)

    Time frame: At completion of Phase Ia dose escalation, after completion of the 21-day DLT assessment period for each dose cohort, up to approximately 15 months after the first participant receives the first dose.

  3. Phase 1a:recommended dose for expansion (RDE)

    Time frame: At completion of Phase Ia dose escalation, after review of DLTs and other available safety data, up to approximately 15 months after the first participant receives the first dose.

  4. Phase Ia/Ib: adverse events (AEs), serious adverse events (SAEs)

    Time frame: From informed consent, during each 21-day treatment cycle, at the end-of-treatment visit (within 7 days of treatment discontinuation), and through 30 days after the last dose or until new anticancer therapy starts, whichever occurs first

  5. Phase Ib: determination of the recommended Phase II dose (RP2D)

    Time frame: From the first dose administered to the first participant in Phase Ia through completion of Phase Ib dose expansion, up to approximately 27 months.

  6. Phase II: Objective response rate (ORR)

    Time frame: From baseline until disease progression, initiation of new anticancer therapy, or withdrawal, assessed up to approximately 24 months.

Secondary outcomes

  1. Phase Ia/Ib/II: maximum plasma concentration (Cmax)

    Time frame: During the first cycle of treatment (21 days)

  2. Phase Ia/Ib/II: time to maximum plasma concentration (Tmax)

    Time frame: During the first cycle of treatment (21 days)

  3. Phase Ia/Ib/II: area under the concentration-time curve (AUC)

    Time frame: During the first cycle of treatment (21 days)

  4. Phase Ia/Ib/II: elimination half-life (t1/2)

    Time frame: During the first cycle of treatment (21 days)

  5. Phase II: Disease Control Rate (DCR)

    Time frame: From baseline until disease progression, initiation of new anticancer therapy, or withdrawal, assessed up to approximately 24 months.

  6. Phase II: adverse events (AEs), serious adverse events (SAEs)

    Time frame: From informed consent, during each 21-day treatment cycle, at the end-of-treatment visit (within 7 days of treatment discontinuation), and through 30 days after the last dose or until new anticancer therapy starts, whichever occurs first.

  7. Phase II: Progression-Free Survival (PFS)

    Time frame: From the first dose until disease progression or death from any cause, whichever occurs first, assessed up to approximately 24 months.

  8. Duration of Response (DoR)

    Time frame: From the first documented CR or PR until disease progression or death from any cause, whichever occurs first, assessed up to approximately 24 months.

  9. Phase II: Time to Response (TTR)

    Time frame: From the first dose until the first documented CR or PR, assessed up to approximately 24 months.

  10. Phase II: Time to Progression (TTP)

    Time frame: From the first dose until disease progression, assessed up to approximately 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2029, 32 months later.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's planned 32 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 8, 2026
StartEst.
Oct 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
1 site added — first site in China
Show site
  • Peking University Cancer Hospital & Institute · Beijing, China
Oct 15, 2026
Registered
First appeared on the registry
Oct 8, 2026
Show all 2 updates
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Peking University Cancer Hospital & Institute · Beijing, China
    + 1 other change: responsible party
  2. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864701
Lead sponsor
Chengdu Anticancer Bioscience, Ltd.
Responsible party
Sponsor
First posted
Oct 8, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Clinical Trial Information Team
Contact
JMBIClinicalTrials@anticancerbio.com
+86 28 85185225

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion